LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060. CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

	Statement of Standalone and Consolidated Un-Audited F	solidated	Un-Audit		inancial Results for the Quarter and Half Year Ended on	s for the C	luarter ar	id Half Ye	ar Ended	on 30-Se	30-September-2020	2020.	
PART-													(Rs. In Lakhs)
				Stand	Standalone					Consol	Consolidated		
20	2201112120		Quarter Ended		Half Year Ended	r Ended	Year Ended		Quarter Ended		Half Year Ended	r Ended	Year Ended
<u>.</u>		30/09/2020 (Un-Audited)	30/06/2020 (Un-Audited)	30/09/2019 (Un-Audited)	30/09/2020 (Un-Audited)	30/09/2019 (Un-Audited)	31/03/2020 (Audited)	30/09/2020 (Un-Audited)	30/06/2020 (Un-Audited)	30/09/2019 (Un-Audited)	30/09/2020 (Un-Audited)	30/09/2019 (Un-Audited)	31/03/2020 (Audited)
~	Income A Pavania From Anarations	12 228 95	10 103 27	11 059 69	22 332 22	20 518 64	37 608 83	12 606 43	10 379 36	11 268 72	22 985 79	20 949 99	38 649 05
	B) Other Income	121.95	197.49	287.60	319.43	445.55	1,213.09	60.18	179.79	252.36	239.98	381.80	1,104.02
	Total Income	12,350.90	10,300.76	11,347.29	22,651.66	20,964.19	38,821.92	12,666.61	10,559.16	11,521.08	23,225.77	21,331.79	39,753.07
7		30 OCF C	00000	2 005 0	67072	70 076 3	20 501 01	20 02	טני נטב נ	07 4 60 4	76 076 7	17 001 1	07 070 61
	A) Cost of Material Consumed D) Purchase of Stock in Trade	2,738.25	2,010.38	3,025.26	4, /48.63 F 027 0E	5,3/8.8/	10,197.06	3,558.06	2,702.30	4,934.60	6,260.36	7,132.64	13,372.62
	B) Fulcilase of Stock-III-11 are (C.) Changes In Trade and WIP	77,63	539.89	21.06	617.52	131.59	(585,50)	134.65	717.15	(35,11)	4,852.84	66.36	(841.34)
	D) Employee Benefits Expenses	1,265.05	1,206.77	1,458.43	2,471.82	2,898.12	5,489.91	1,362.21	1,292.06	1,541.23	2,654.27	3,065.70	5,865.38
	E) Finance Costs	20.66	33.66	57.18	54.32	121.58	198.36	(7.86)	67.39	58.05	59.53	122.64	201.76
	F) Deprecation and Amortisation Expense	142.02	140.55	129.92	282.57	269.42	546.95	189.45	187.82	177.12	377.27	361.80	732.62
	G) Other Expenses	2,113.44	1,628.81	1,624.93	3,742.25	3,436.10	7,504.26	2,252.45	1,770.80	1,705.16	4,023.25	3,623.20	7,938.84
	Total Expenses	9,611.64	8,233.43	8,985.59	17,845.06	16,902.52	32,417.27	9,811.59	8,417.72	9,035.78	18,229.31	17,061.53	33,029.83
ω.	Profit / (Loss) Before Exceptional Items & Tax (1-2)	2,739.26	2,067.33	2,361.70	4,806.59	4,061.67	6,404.65	2,855.02	2,141.43	2,485.30	4,996.46	4,270.25	6,723.24
4		Z	Z	NII	IN	Z	N	IN.	N	N	IN	IN	Z
2	Profit / (Loss) after Exceptional items but Before Tax (3-4)	2,739.26	2,067.33	2,361.70	4,806.59	4,061.67	6,404.65	2,855.02	2,141.43	2,485.30	4,996.46	4,270.25	6,723.24
,	Tax Expense		i	1				0	1000	000	0		
٥	A) Current Tax (Net)	704.00	536.00	15.08	1,240.00	989.80	1,470.01	139.83	21 56	19.683	1,323.59	1,035.89	1,566.96
	B. Defetted Tax (Net.) Short / Excess Provision of Income Tax of Previous Years	<u> </u>	SZ:25	NE NE	î.	69.31	1.92	10.13) II	S IN	10.13	69.31	5.62
7	Profit / Loss For The Period (5-6)	2,019.76	1,499.08	1,798.83	3,518.84	3,015.28	4,956.35	2,092.24	1,526.12	1,892.79	3,618.35	3,160.45	5,146.63
c		Ž	ž	17	2	ž	2	7	100	7	7	ò	,
0	Non-Controlling Interest	2 010 7	1 409 08	1 798 83	2 5 1 8 8 4	3 015 28	4 956 35	2 001 10	1 525 74	1 801 45	3 616 93	2 158 30	5 143 92
6		(10.99)	(10.99)	1.09	(21.97)	2.213.23	(43.94)	(11.55)	(11.55)	0.82	(23.09)	1.65	(46.18)
19		2,008.77	1,488.10	1,799.91	3,496.87	3,017.45	4,912.41	2,079.64	1,514.20	1,892.27	3,593.84	3,160.04	5,097.74
1		2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00
12	Ŭ						28,449.47						29,308.89
,	Earnings Per Share (of Rs. 10/	9	1		1	1			Î		0	1	i i
<u>-</u>	(a) Basic (b) Niluted	10.10	7.50	8,99	17.59	15.08	24.78	10.46	7.63	9.46	18.08	15.79	25.72
	Soc accompanying notes to the Einancial Descriptor	?		5		2	0.114	2	1 22 2	T,	2		1

Digitally signed by
MAHENDRAB MAHENDRABHAI G
PATEL
HAI G PATEL
Date: 2020.11.03 13:45:12 +05'30'



NOTES:					
1	The Financial Results of the Company for the Quarter and Half Year Ended September 30, 2020 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on November 03, 2020. The Statutory Auditors of the Company have carried out Limited Review of these Results and the Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.				
2	These Financial Results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.				
3	Pursuant to order passed by Hon'ble National Company Law Tribunal, Ahmedabad Bench on September 17, 2020, the meeting of the members of the Company was held on October 29, 2020 through VC / OAVM to consider and approve the scheme of amalgamation of Lincoln Parenteral Limited ("Transferor Company") with Lincoln Pharmaceuticals Limited ("Transferee Company") and their respective Shareholders and Creditors ("Scheme"). The scheme has been approved by members with requisite majority.				
4	Segment reporting as defined in IND-AS 108 is not applicable, since the Company has only one reportable segment i.e. Pharmaceuticals.				
5	Comparative figures have been rearranged/regrouped wherever necessary.				
6	Consolidated Results includes results of its subsidiaries.				
7	The impact of CoVID-19 may be different from what is estimated as at such date of approval of the financial results of the Company will continue to monitor any material changes to future economic conditions.				
For Lincoln Pharmaceuticals Limited					

For Lincoln Pharmaceuticals Limited MAHENDRAB Digitally signed by MAHENDRABHAI G PATEL

HAI G PATEL Date: 2020.11.03 13:45:50 +05'30'

Mahendra G. Patel **Managing Director** DIN: 00104706

Place: Ahmedabad

Date: November 03, 2020





Notes: 8							
		Stand			lidated		
Sr. No.	Particulars	As at	As at	As at	As at		
31. NO.	Fai ticulai S	30/09/2020	31/03/2020	30/09/2020	31/03/2020		
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)		
Α	ASSETS						
1	Non-Current Assets						
	(A) Property, Plant and Equipment	8,822.37	9,036.01	10,983.58	11,282.83		
	(B) Right to use asset	28.62	29.70	28.62	29.70		
	(C) Capital Work-In-Progress	15.39	4.03	18.41	4.03		
	(D) Goodwill	Nil	Nil	922.56	922.56		
	(E) Other Intangible Assets	30.96	36.93	30.96	36.94		
	(F) Financial Assets						
	(i) Non-Current Investments	2,578.63	2,578.62	8.56	8.55		
	(ii) Loans	1,478.17	1,478.17	1,478.17	1,478.17		
	(iii) Others financial assets	1,756.71	1,684.03	26.99	17.85		
	(G) Other Non-Current Assets	247.12	335.75	263.26	358.44		
	Sub Total Non-Current Assets	14,957.97	15,183.24	13,761.11	14,139.07		
2	Current Assets	,.	10,100121	10,10	,		
_	(A) Inventories	3,405.80	3,753.73	4,037.32	4,739.60		
	(B) Financial Assets	0,100.00	0,700.70	1,007.02	1,707.00		
	(i) Current Investments	7,243.46	3,421.63	7,243.46	3,421.63		
	(ii) Trade Receivables	10,776.05	9,099.29	11,811.61	10,133.59		
	(iii) Cash and Cash Equivalents	2,553.38	892.30	3,076.47	1,223.06		
	(iv) Other Bank Balances	236.16	228.91	242.32	235.09		
	(v) Loans	1,608.34	1,441.70	1,738.34	1,588.40		
	(vi) Other Financial Assets	148.43	123.01	18.14	13.67		
	(C) Current Tax Assets (Net)	146.43 Nil	123.01 Nil	0.11	0.11		
	(D) Other Current Assets	1,719.94	2,577.14	2,863.51	3,444.56		
	Sub Total Current Assets	27,691.56	21,537.71	31,031.28	24,799.71		
	TOTAL ASSETS (1+2)	42,649.53	36,720.95	44,792.39	38,938.78		
ъ	EQUITY AND LIABILITIES	42,049.53	30,720.95	44,192.39	30,730.70		
В 1							
ı	Equity (A) Share Conite!	2 000 00	2 000 00	2 000 00	2 000 00		
	(A) Share Capital	2,000.00	2,000.00	2,000.00	2,000.00		
	(B) Other Equity	31,946.36	28,449.47	32,902.73	29,308.89		
	(C) Non-Controlling Interest	Nil	Nil	39.60	38.20		
•	Sub Total Equity	33,946.36	30,449.47	34,942.33	31,347.09		
2	Non-Current Liabilities						
	(A) Financial Liabilities	00.77	F4 07	00.77	04.00		
	(i) Borrowings	33.77	51.97	33.77	84.89		
	(ii) Other Financial Liabilities	400.59	405.22	400.59	405.24		
	(B) Deferred Tax Liabilities (Net)	306.02	267.29	578.23	543.30		
_	Sub Total Non-Current Liabilities	740.38	724.48	1,012.59	1,033.43		
3	Current Liabilities						
	(A) Financial Liabilities						
	(i) Borrowings	1,784.17	383.32	1,784.17	383.32		
	(ii) Trade Payables						
	(a) Due to MSME	833.81	654.39	952.45	799.13		
	(b) Due to Other than MSME	3,749.04	3,545.59	4,362.75	4,325.13		
	(iii) Other Financial Liabilities	791.04	596.95	827.92	611.12		
	(B) Other Current Liabilities	184.13	250.03	214.02	301.49		
	(C) Provisions	30.60	43.60	31.38	44.38		
	(D) Current Tax Liabilities (Net)	590.00	73.12	664.76	93.69		
	Sub Total Current Liabilities	7,962.78	5,546.99	8,837.46	6,558.26		
	TOTAL EQUITY AND LIABILITIES (1+2+3)	42,649.53	36,720.95	44,792.39	38,938.78		
	. , ,			incoln Pharmac			

For Lincoln Pharmaceuticals Limited

MAHENDRAB Digitally signed by MAHENDRABHAI G PATEL Date: 2020.11.03 13:46:04 +05'30'

Place: Ahmedabad Date: November 03, 2020 Mahendra G. Patel Managing Director DIN: 00104706

Notes: 9 STANDALONE AND CONSOL	7			(Rs. In Lakhs)	
		Standalone		Consilidated	
Particulars	Half Year Ended	Year Ended	Half Year Ended	Year Ended	
	30-Sept-2020	31-March-2020	30-Sept-2020	31-March-2020	
Coch Flow From Operating Activities	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	
Cash Flow From Operating Activities Profit Before Tax	4,806.59	6 101 65	4,996.46	6 722 24	
Profit before Tax	4,000.39	6,404.65	4,990.40	6,723.24	
Adjustments For:					
Depreciation and Amortisation Expense	282.57	546.95	377.27	732.62	
Amortisation of Lease Premium	Nil	Nil	Nil	Nil	
Finance Costs	54.32	198.36	59.53	201.76	
Provision For Expected Credit Loss	(31.19)	3.45	(31.83)	4.24	
Bad Debt Written off	200.00	180.11	200.01	207.49	
MTM (Gain) / Loss on Fair Valuation of Derivative Financial					
Instruments	(42.64)	45.60	(42.64)	45.60	
Loss on Sale of Assets (Net)	Nil	4.02	Nil	4.02	
Interest Income	(101.56)	(255.73)	(38.78)	(150.03)	
Share of Profit from Subsidiaries	(20.95) (115.27)	(5.36)	Nil (115.27)	Nil	
(Gain) / Loss on Fair Valuation of Mutual Funds Profit on Sale of Current Investment	(6.69)	(169.98) (9.57)	(115.27) (6.69)	(169.98)	
Operating Profit Before Working Capital Changes	5,025.19	6,942.50	5,398.06	(9.57) 7,589.39	
operating Front Before Working Capital Glianges	3,023.17	0,742.30	3,370.00	1,307.37	
Changes In Operating Assets and Liabilities:				l	
(Increase)/Decrease In Inventories	347.92	(806.33)	702.29	(1,117.03)	
(Increase)/Decrease In Trade Receivables	(1,845.33)	2,016.96	(1,846.22)	1,901.62	
(Increase)/Decrease In Other Non Current Financial Assets	(13.37)	(3.77)	(12.63)	(4.97)	
(Increase)/Decrease In Other Current Financial Assets	(4.47)	1.60	(4.47)	2.70	
(Increase)/Decrease In Other Non Current Assets	12.53	(18.89)	10.53	(18.89)	
(Increase)/Decrease In Other Current Assets	825.90	(289.05)	581.05	7.77	
Increase/(Decrease) In Trade Payable	382.97	629.08	190.94	722.80	
Increase/(Decrease) in Other Current Financial Liabilities	306.20	(197.15)	334.40	(295.03)	
Increase/(Decrease) in Other Non Current Financial Liabilities	(4.65)	37.70	(4.65)	37.74	
Increase/(Decrease) In Other Current Liabilities	(65.90)	174.88	(87.46)	217.11	
Increase/(Decrease) In Short-Term Provisions Cash Flow Generated From Operations	(13.00) 4,953.99	(18.39) 8,469.14	(45.55) 5,216.30	(20.71) 9,022.50	
Direct Taxes Paid (Net)	(652.24)	(1,398.06)	(680.62)	(1,480.97)	
NET CASH FLOW FROM OPERATING ACTIVITIES (A)	4,301.75	7,071.08	4,535.68	7,541.53	
	.,	1,011.00	.,000.00	77011100	
Cash Flows From Investing Activities					
Purchase of Property, Plant and Equipment	(137.49)	(666.92)	(152.65)	(769.08)	
Proceeds From Sale of Property, Plant and Equipments	Nil	50.76	Nil	50.76	
Margin Money Deposit	Nil	(17.29)	Nil	(23.45)	
Interest Received	38.77	139.72	38.78	150.84	
(Increase)/Decrease in Non Current Financial Assets	Nil	101.07	Nil	101.08	
(Increase)/Decrease in Current Financial Assets	(166.64)	(1,266.70)	(149.93)	(1,163.40)	
Dividend received Sale of Current Investment	Nil	Nil	Nil 1,050.50	Nil 600.00	
Purchase of Current Investment	1,050.50 (4,750.38)	600.00 (2,035.00)	(4,750.38)	(2,035.00)	
Amount received from Equity Instrument of Subsidiary	(4,750.36) Nil	(2,035.00)	(4,750.36) Nil	(2,035.00) Nil	
NET CASH FLOW FROM INVESTING ACTIVITIES (B)	(3,965.24)	(2,899.36)	(3,963.69)	(3,088.25)	
NET CASITIES WITHOUT HAVESTING ACTIVITIES (B)	(5,703.24)	(2,077.00)	(3,703.07)	(0,000.23)	
Cash Flows From Financing Activities					
Proceeds of Long Term Borrowings	Nil	40.00	Nil	81.00	
Repayment of Long-Term Borrowings	(16.72)	(305.38)	(54.66)	(308.43)	
Proceeds of Short Term Borrowings	Nil	Nil	1,400.85	Nil	
Repayment of Short-Term Borrowings	1,400.85	(2,626.03)	Nil	(2,626.03)	
Dividend Paid on Equity Shares (incl. Tax Thereon)	Nil	(723.34)	Nil	(723.34)	
Finance Costs Paid	(59.56)	(195.61)	(64.77)	(199.09)	
NET CASH FLOW FROM FINANCING ACTIVITIES (C)	1,324.58	(3,810.36)	1,281.42	(3,775.89)	
NET INCREASED IN CASH AND CASH EQUIVALENTS (A + B		0/4.67	4.050.55	/77.60	
+ C) Cosh and Cosh Equivalents at the Reginning of the Vegr	1,661.09	361.36	1,853.41	677.39	
Cash and Cash Equivalents at the Beginning of the Year	892.30	530.94	1,223.06	545.67	
Cash and Cash Equivalents at the End of the Year	2,553.39	892.30	3,076.47	1,223.06	
Notes: (i). Components of Cash and Cash Equivalents at each Balance Shee	t Dato:				
(i). Components of Cash and Cash Equivalents at each balance shee	Half Year Ended	Year Ended	Half Year Ended	Year Ended	
Particulars	30-Sept-2020	31-March-2020	30-Sept-2020	31-March-2020	
Cash on hand	22.71	34.36	27.06	39.48	
Balances with Bank	2,530.68	857.94	3,049.41	1,183.58	
	2,000.00	307.74	5,017.71	.,100.00	

The above Cash flow statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard-7, "Statement of Cash Flows".

2,553.39

892.30

For Lincoln Pharmaceuticals Limited

MAHENDRAB Digitally signed by MAHENDRABHAI G PATEL Date: 2020.11.03 13:46:20 +05'30'

3,076.47

Place: Ahmedabad

Total Cash and cash equivalents (Refer Note 15)

Date: November 03, 2020

Mahendra G. Patel Managing Director DIN: 00104706

1,223.06